Transcriptome and Metabolome based candidate mechanism of BCR-ABL independent resistance to Olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

Olverembatinib represents the third-generation breakpoint cluster region protein-Abelson-murine leukemia 1 (BCR-ABL1) tyrosine kinase inhibitor (TKI) with oral bioavailability, which can be used to overcome the T315I mutation in Philadelphia chromosome-positive (Ph+) leukemia. BCR-ABL independent resistance to Olverembatinib has been reported among patients in various clinical cases. However, the mechanism of Olverembatinib resistance has rarely been reported. This study has illustrated bone marrow cell transcriptome and Metabolome profiles among Ph + acute lymphoblastic leukemias (ALL) cases pre- and post-Olverembatinib resistance. The transcriptome studies demonstrated that PI3K/AKT, purine metabolism, and other signaling pathways could play a vital role in Olverembatinib resistance. As suggested by metabolomics, Olverembatinib resistance in Ph + ALL was associated with purine metabolism alterations. Subsequently, High-Performance Liquid Chromatography (HPLC) along with Real-time Quantitative PCR (RT-qPCR) was utilized to measure purine metabolism-related mRNA levels and metabolism expression levels between Olverembatinib resistance and sensitive cell lines. Our results elucidate the mechanism of Olverembatinib resistance in Ph + ALL at transcriptome and metabolome levels, which facilitate a better understanding of Olverembatinib resistance and hence may prove crucial in identifying novel drugs to tackle this conundrum.